APOE interacts with ACE2 inhibiting SARS-CoV-2 cellular entry and inflammation in COVID-19 patients. 2022

Hongsheng Zhang, and Lin Shao, and Zhihao Lin, and Quan-Xin Long, and Huilong Yuan, and Lujian Cai, and Guangtong Jiang, and Xiaoyi Guo, and Renzhi Yang, and Zepeng Zhang, and Bingchang Zhang, and Fan Liu, and Zhiyong Li, and Qilin Ma, and Yun-Wu Zhang, and Ai-Long Huang, and Zhanxiang Wang, and Yingjun Zhao, and Huaxi Xu
Center for Brain Sciences, the First Affiliated Hospital of Xiamen University, Institute of Neuroscience, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Xiamen University, Xiamen, China.

Apolipoprotein E (APOE) plays a pivotal role in lipid including cholesterol metabolism. The APOE ε4 (APOE4) allele is a major genetic risk factor for Alzheimer's and cardiovascular diseases. Although APOE has recently been associated with increased susceptibility to infections of several viruses, whether and how APOE and its isoforms affect SARS-CoV-2 infection remains unclear. Here, we show that serum concentrations of APOE correlate inversely with levels of cytokine/chemokine in 73 COVID-19 patients. Utilizing multiple protein interaction assays, we demonstrate that APOE3 and APOE4 interact with the SARS-CoV-2 receptor ACE2; and APOE/ACE2 interactions require zinc metallopeptidase domain of ACE2, a key docking site for SARS-CoV-2 Spike protein. In addition, immuno-imaging assays using confocal, super-resolution, and transmission electron microscopies reveal that both APOE3 and APOE4 reduce ACE2/Spike-mediated viral entry into cells. Interestingly, while having a comparable binding affinity to ACE2, APOE4 inhibits viral entry to a lesser extent compared to APOE3, which is likely due to APOE4's more compact structure and smaller spatial obstacle to compete against Spike binding to ACE2. Furthermore, APOE ε4 carriers clinically correlate with increased SARS-CoV-2 infection and elevated serum inflammatory factors in 142 COVID-19 patients assessed. Our study suggests a regulatory mechanism underlying SARS-CoV-2 infection through APOE interactions with ACE2, which may explain in part increased COVID-19 infection and disease severity in APOE ε4 carriers.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000085962 Angiotensin-Converting Enzyme 2 A transmembrane glycoprotein with an extracellular catalytic domain which functions as a carboxypeptidase. It cleaves a single C-terminal residue from a distinct range of substrates. The catalytic efficiency is 400-fold higher with ANGIOTENSIN II as a substrate than with ANGIOTENSIN I. Angiotensin-converting enzyme 2 is also is a functional receptor for the spike glycoprotein (SPIKE PROTEIN, CORONAVIRUS) of the CORONAVIRUSES SARS-COV, SARS-COV2, and HCOV-NL63. ACE-Related Carboxypeptidase,ACE2 Angiotensin-Converting Enzyme Protein 2,ACE2 Enzyme,ACE2 Protein,Angiotensin Converting Enzyme 2,Angiotensin-Converting Enzyme-Related Carboxypeptidase,ACE Related Carboxypeptidase,ACE2 Angiotensin Converting Enzyme Protein 2,Angiotensin Converting Enzyme Related Carboxypeptidase,Carboxypeptidase, ACE-Related,Carboxypeptidase, Angiotensin-Converting Enzyme-Related
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D053318 Apolipoprotein E3 A 34-kDa glycosylated protein. A major and most common isoform of apolipoprotein E. Therefore, it is also known as apolipoprotein E (ApoE). In human, Apo E3 is a 299-amino acid protein with a cysteine at the 112 and an arginine at the 158 position. It is involved with the transport of TRIGLYCERIDES; PHOSPHOLIPIDS; CHOLESTEROL; and CHOLESTERYL ESTERS in and out of the cells. APOE-epsilon 3,APOE-epsilon3,Apo E-3,Apo E3,ApoE3,Apolipoprotein E-3,Apolipoprotein E-epsilon3,Isoapolipoprotein E3,APOE epsilon 3,APOE epsilon3,Apo E 3,Apolipoprotein E 3,Apolipoprotein E epsilon3
D053327 Apolipoprotein E4 A major and the second most common isoform of apolipoprotein E. In humans, Apo E4 differs from APOLIPOPROTEIN E3 at only one residue 112 (cysteine is replaced by arginine), and exhibits a lower resistance to denaturation and greater propensity to form folded intermediates. Apo E4 is a risk factor for ALZHEIMER DISEASE and CARDIOVASCULAR DISEASES. Apo E epsilon 4,Apo E-4,Apo E4,ApoE4,Apolipoprotein E-4,Apo E 4,Apolipoprotein E 4

Related Publications

Hongsheng Zhang, and Lin Shao, and Zhihao Lin, and Quan-Xin Long, and Huilong Yuan, and Lujian Cai, and Guangtong Jiang, and Xiaoyi Guo, and Renzhi Yang, and Zepeng Zhang, and Bingchang Zhang, and Fan Liu, and Zhiyong Li, and Qilin Ma, and Yun-Wu Zhang, and Ai-Long Huang, and Zhanxiang Wang, and Yingjun Zhao, and Huaxi Xu
October 2021, Topics in current chemistry (Cham),
Hongsheng Zhang, and Lin Shao, and Zhihao Lin, and Quan-Xin Long, and Huilong Yuan, and Lujian Cai, and Guangtong Jiang, and Xiaoyi Guo, and Renzhi Yang, and Zepeng Zhang, and Bingchang Zhang, and Fan Liu, and Zhiyong Li, and Qilin Ma, and Yun-Wu Zhang, and Ai-Long Huang, and Zhanxiang Wang, and Yingjun Zhao, and Huaxi Xu
December 2020, Medical hypotheses,
Hongsheng Zhang, and Lin Shao, and Zhihao Lin, and Quan-Xin Long, and Huilong Yuan, and Lujian Cai, and Guangtong Jiang, and Xiaoyi Guo, and Renzhi Yang, and Zepeng Zhang, and Bingchang Zhang, and Fan Liu, and Zhiyong Li, and Qilin Ma, and Yun-Wu Zhang, and Ai-Long Huang, and Zhanxiang Wang, and Yingjun Zhao, and Huaxi Xu
December 2020, The Malaysian journal of pathology,
Hongsheng Zhang, and Lin Shao, and Zhihao Lin, and Quan-Xin Long, and Huilong Yuan, and Lujian Cai, and Guangtong Jiang, and Xiaoyi Guo, and Renzhi Yang, and Zepeng Zhang, and Bingchang Zhang, and Fan Liu, and Zhiyong Li, and Qilin Ma, and Yun-Wu Zhang, and Ai-Long Huang, and Zhanxiang Wang, and Yingjun Zhao, and Huaxi Xu
June 2021, Biomedical journal,
Hongsheng Zhang, and Lin Shao, and Zhihao Lin, and Quan-Xin Long, and Huilong Yuan, and Lujian Cai, and Guangtong Jiang, and Xiaoyi Guo, and Renzhi Yang, and Zepeng Zhang, and Bingchang Zhang, and Fan Liu, and Zhiyong Li, and Qilin Ma, and Yun-Wu Zhang, and Ai-Long Huang, and Zhanxiang Wang, and Yingjun Zhao, and Huaxi Xu
July 2021, Cells,
Hongsheng Zhang, and Lin Shao, and Zhihao Lin, and Quan-Xin Long, and Huilong Yuan, and Lujian Cai, and Guangtong Jiang, and Xiaoyi Guo, and Renzhi Yang, and Zepeng Zhang, and Bingchang Zhang, and Fan Liu, and Zhiyong Li, and Qilin Ma, and Yun-Wu Zhang, and Ai-Long Huang, and Zhanxiang Wang, and Yingjun Zhao, and Huaxi Xu
August 2021, Chemical biology & drug design,
Hongsheng Zhang, and Lin Shao, and Zhihao Lin, and Quan-Xin Long, and Huilong Yuan, and Lujian Cai, and Guangtong Jiang, and Xiaoyi Guo, and Renzhi Yang, and Zepeng Zhang, and Bingchang Zhang, and Fan Liu, and Zhiyong Li, and Qilin Ma, and Yun-Wu Zhang, and Ai-Long Huang, and Zhanxiang Wang, and Yingjun Zhao, and Huaxi Xu
January 2021, International journal of biological sciences,
Hongsheng Zhang, and Lin Shao, and Zhihao Lin, and Quan-Xin Long, and Huilong Yuan, and Lujian Cai, and Guangtong Jiang, and Xiaoyi Guo, and Renzhi Yang, and Zepeng Zhang, and Bingchang Zhang, and Fan Liu, and Zhiyong Li, and Qilin Ma, and Yun-Wu Zhang, and Ai-Long Huang, and Zhanxiang Wang, and Yingjun Zhao, and Huaxi Xu
November 2022, Molecular biology reports,
Hongsheng Zhang, and Lin Shao, and Zhihao Lin, and Quan-Xin Long, and Huilong Yuan, and Lujian Cai, and Guangtong Jiang, and Xiaoyi Guo, and Renzhi Yang, and Zepeng Zhang, and Bingchang Zhang, and Fan Liu, and Zhiyong Li, and Qilin Ma, and Yun-Wu Zhang, and Ai-Long Huang, and Zhanxiang Wang, and Yingjun Zhao, and Huaxi Xu
April 2021, Journal of hematology & oncology,
Hongsheng Zhang, and Lin Shao, and Zhihao Lin, and Quan-Xin Long, and Huilong Yuan, and Lujian Cai, and Guangtong Jiang, and Xiaoyi Guo, and Renzhi Yang, and Zepeng Zhang, and Bingchang Zhang, and Fan Liu, and Zhiyong Li, and Qilin Ma, and Yun-Wu Zhang, and Ai-Long Huang, and Zhanxiang Wang, and Yingjun Zhao, and Huaxi Xu
August 2022, Microbiology spectrum,
Copied contents to your clipboard!